CinqAir
Total Payments
$1.8M
Transactions
616
Doctors
4
Companies
1
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2017 | $1.8M | 616 | 4 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $1.8M | 616 | 100.0% |
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| C38072-AS-30025 | Teva Pharmaceuticals USA, Inc. | $604,093 | 2 |
| C38072-AS-30066 | Teva Pharmaceuticals USA, Inc. | $583,915 | 2 |
| C38072-AS-10069 | Teva Pharmaceuticals USA, Inc. | $228,497 | 0 |
| C38072-PK-10071 | Teva Pharmaceuticals USA, Inc. | $121,363 | 0 |
| C38072-AS-30027 | Teva Pharmaceuticals USA, Inc. | $107,312 | 0 |
| Efficacy of Reslizumab for the treatment of Chronic Sinusitis | Teva Pharmaceuticals USA, Inc. | $92,705 | 0 |
| Reslizumab in the Treatment of EGPA | Teva Pharmaceuticals USA, Inc. | $46,329 | 0 |
| C38072/3085 | Teva Pharmaceuticals USA, Inc. | $15,195 | 0 |
Top Doctors Receiving Payments for CinqAir
Ad
Manufacturing Companies
Product Information
- Type Drug
- Total Payments $1.8M
- Total Doctors 4
- Transactions 616
About CinqAir
CinqAir is a drug associated with $1.8M in payments to 4 healthcare providers, recorded across 616 transactions in the CMS Open Payments database. The primary manufacturer is Teva Pharmaceuticals USA, Inc..
Payment data is available from 2017 to 2017. In 2017, $1.8M was paid across 616 transactions to 4 doctors.
The most common payment nature for CinqAir is "Unspecified" ($1.8M, 100.0% of total).
CinqAir is associated with 8 research studies, including "C38072-AS-30025" ($604,093).